GlassScriptPhysician profile
Rita E Plemmons-Winfield
NPI 1467457861
$3,873.26
in general payments reported to CMS, 2019-2025
31 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $630 · 2021: $61.43 · 2022: $452 · 2023: $557 · 2024: $855 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $588.61 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $340.35 | 2019-2025 | |
| Abbvie INC. | $314.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $251.25 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $187.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $183.34 | 2019-2023 | Veozah |
| Allergan, INC. | $180.70 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.22 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $93.87 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.32 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $69.24 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $69.18 | 2022-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $63.58 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $49.60 | 2024-2025 | Givlaari |
| Amarin Pharma, INC. | $48.89 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $39.90 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $37.19 | 2022 | |
| Genentech USA, INC. | $33.96 | 2019 | |
| Exact Sciences Corporation | $33.38 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Ardelyx, INC. | $24.58 | 2025 | Ibsrela |
| Antares Pharma, INC. | $24.14 | 2022 | |
| Eisai INC. | $22.28 | 2024 | |
| Philips North America LLC | $19.92 | 2024 | (Ck7) Extended Holter |
| Inogen, INC. | $19.15 | 2022 | |
| Medtronic, INC. | $18.75 | 2024 | Minimed 780g |
| Dexcom, INC. | $18.52 | 2022 | |
| Sumitomo Pharma America, INC. | $16.94 | 2024 | Gemtesa |
| Mylan Specialty L.P. | $14.49 | 2019 | |
| Horizon Therapeutics Plc | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Plemmons-Winfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.